Menu
← Oncology Approval Tracker
FDA DECISION ·
Tevimbra
tislelizumab-jsgr · BeOne Medicines USA
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adds 400 mg IV every six weeks as monotherapy in adults with unresectable or metastatic ESCC after systemic chemotherapy without a PD-1 or PD-L1 inhibitor.
LAMPGEN ANALYSIS
Why it matters
A six-week interval adds a less frequent option for the existing post-chemotherapy monotherapy indication.
What research teams should watch
Review how to continue toxicity and disease monitoring between less frequent infusion visits.
PRIMARY RECORDS